Soluble biomarker signature to predict outcome of patients with non-small-cell lung cancer (NSCLC) treated with anti-PD1/PDL1 monoclonal antibodies.

• DOI: 10.1200/jco.2019.37.15_suppl.e20685
• Publication Date: 2019-05-28T13:57:12Z
• Authors: Javier Garde-Noguera; Eloisa Jantus-Lew...; Sandra Gallach; Jose Vidal-Martinez; Ana Blasco; Jose Garcia Sanchez; Feiyu Zhang; Francisco Aparisi; Beatriz Honrubia ...; Lauren Condori Fa...; Susana Torres Mar...; Nuria Piera Molons; J. Murado-Pardo; R. Gisbert-Criado; Silvia Calabuig-F...; Carlos Camps

e20685 Background: Immunotherapy with anti-PD1/PDL1 monoclonal antibodies has become the second line standard treatment for most patients diagnosed of advanced Non-Small-Cell lung cancer (NSCLC). The aim this study is to assess utility circulating biomarkers such as sPDL1, sPDL2, sCD137, sIDO, sTIM3, sCD28, sCD27, sCTLA4, sHVEM, sLAG3, sCD80 and sGITR predicting efficacy immunotherapy therapies. Methods: Blood samples were collected before from 50 NSCLC who received anti PD1/PDL1 therapies (second line). Plasma biomarkers´ levels measured by Multiplex bead-based assays. Continuous variables categorized using median a cut-off. Non parametric test used correlations between analytical clinical-pathological parameters response rate analysis. For survival analysis (progression free survival-PFS overall survival-OS) Kaplan Meier curves long-rank performed. Results: met inclusion criteria. Biomarkers associated better outcome in terms Response Rate or PFS sCD137 sGITR. Median plasma sIDO 80.5, 168.7, 64.92s 114.43 ng/ml respectively. ORR was higher high CD137 (75 vs 25%, p = 0.28), GITR (83.3 16.7%, 0.009) sPDL1 (66.7 33.3%, 0.07). significantly (NR 3 months, 0.017), there favourable trend serum 5.07, 0.11), 5.57 0.08); (14.33 0.16). Combination these allowed identification three groups: group1 (0-1 positive biomarker), group2 (2 biomarkers) group (3 4 biomarkers), significant differences (8.3 25 66.7%, 0.01), (median 3.2, 1.1 NR 0.01) OS 2.3, 5.0 0.02). Conclusions: Circulating immune markers can be reliable detected patients. In treated anti-PD1 antibodies. seem related degree PFS. might helpful predict treatment.